Skip to main content
SpringerLink
Log in

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Modern treatment strategies have resulted in an excellent overall survival in the majority of patients with Hodgkin’s lymphoma. PET-stratification is used to guide treatment in patients with limited disease in clinical trials, but recent results indicate that combined treatment with chemotherapy and radiotherapy is still the standard of care. Prediction of treatment related mortality and new data about chemotherapy induced infertility will guide our decisions especially in patients with advanced disease and brentuximab vedotin is now an approved option in patients with relapsed or refractory disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. DeVita VT, Jr. A selective history of the therapy of Hodgkin’s disease. Br J Haematol. 2003;122(5):718–27.

    Article  PubMed  Google Scholar 

  2. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;11.

  3. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  PubMed  CAS  Google Scholar 

  4. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.

    Article  PubMed  Google Scholar 

  5. Wongso D, Plutschow A, Fuchs M, Haverkamp H, Klimm B, Sasse S, et al. Treatment-related mortality in patients undergoing therapy for advanced Hodgkin’s lymphoma: analysis of the German Hodgkin Study Group (GHSG). Onkologie. 2012;35:169–70.

    Google Scholar 

  6. Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, et al. Assessment of male fertility in patients with Hodgkin’s lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008;19(10):1795–801.

    Article  PubMed  CAS  Google Scholar 

  7. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.

    Article  PubMed  CAS  Google Scholar 

  8. Josting A, Muller H, Borchmann P, Baars JW, Metzner B, Dohner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010;28(34):5074–80.

    Article  PubMed  Google Scholar 

  9. Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522–9.

    Article  PubMed  Google Scholar 

  10. Goda JS, Massey C, Kuruvilla J, Gospodarowicz MK, Wells W, Hodgson DC, et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2012;84(3):e329–35.

    Article  PubMed  Google Scholar 

  11. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.

    Article  PubMed  CAS  Google Scholar 

  12. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.

    Article  PubMed  CAS  Google Scholar 

  13. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–81.

    Article  PubMed  CAS  Google Scholar 

  14. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There are no relevant conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Salzburger Landeskliniken, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, 5020, Salzburg, Austria

    Thomas Melchardt, Lukas Weiss, Richard Greil &  Alexander Egle MD

Authors
  1. Thomas Melchardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lukas Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Greil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Egle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Egle MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melchardt, T., Weiss, L., Greil, R. et al. What’s new in Hodgkin’s lymphoma: ASH 2012 and more. memo 6, 193–196 (2013). https://doi.org/10.1007/s12254-013-0095-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-013-0095-7

Keywords

Search

Navigation